Delivery Order SPE2DB22D2206-SPE2DB25FJP86
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $4,349.27 to AmerisourceBergen Drug Corp for the supply of Linzess 145 microgram capsules (30-count units) with an ultimate completion date of July 31, 2025. This competitive award, issued on July 30, 2025, utilizes firm fixed pricing with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will fulfill this order from its corporate office location....
- The Defense Logistics Agency awarded a $11,335.78 delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Linzess 290 microgram capsules in quantities of 30 units. This firm fixed-price contract represents a competitively awarded, non-set-aside procurement with a completion date of August 19, 2025. The product will be performed and delivered from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp valued at $2,386.99 for the supply of Linzess 145 mcg capsules (30-unit quantity) with an ultimate completion date of August 5, 2025. This contract represents a firm fixed-price delivery order with no set-aside designation, indicating competitive award through open procurement. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order valued at $2,321.41 to AmerisourceBergen Drug Corp for the supply of Linzess 290 micrograms capsules (30-count units). This competitively awarded, firm fixed-price delivery order was executed on August 20, 2025, with an ultimate completion date of August 21, 2025. The contract represents a small-value pharmaceutical supply transaction fulfilled from AmerisourceBergen's place of performance in Conshohocken, Pennsylvania, where the company...
- The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a global pharmaceutical distribution company. The contract is for the supply of LINZESS 145 MCG capsules to DLA Troop Support Medical, with a ceiling value of $1,198.63 and a performance period through April 2, 2024. This delivery order is part of a larger indefinite delivery contract (IDC) awarded to Amerisourcebergen Drug Corp,...
- The Defense Logistics Agency awarded a delivery order valued at $1,392.69 to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Linzess 290 microgram capsules (30-count unit dose). This is a firm fixed price, competitive delivery order with no set-aside designation and an ultimate completion date of August 11, 2025. The order will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $2,333.53 to AmerisourceBergen Drug Corp for Linzess 72 mcg capsules (30-count units) on August 5, 2025, with an ultimate completion date of August 6, 2025. This competitively awarded, firm fixed-price delivery order was performed at the contractor's facility in Conshohocken, Pennsylvania. The contract carries no set-aside designation, indicating it was competed among all eligible vendors in the open market. This delivery order is...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $5,000.53 to AmerisourceBergen Drug Corp for the supply of Linzess 72 mcg capsules (30-count units) on August 4, 2025, with completion targeted for August 5, 2025. This firm fixed price delivery order was awarded without set-aside restrictions through competitive procurement. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order operates under...
- The Defense Logistics Agency awarded a delivery order valued at $1,064.49 to AmerisourceBergen Drug Corp for Linzess 290 microgram capsules (30-count units) on August 7, 2025, with an ultimate completion date of August 8, 2025. This firm fixed-price delivery order represents a non-competitive set-aside award and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions...
- The Defense Logistics Agency awarded a delivery order valued at $22,453.20 to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Linzess 145 microgram capsules (30-count units). This is a firm fixed-price, non-set-aside contract with an ultimate completion date of August 18, 2025, and performance based in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at...
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB25FJP86Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,599.95 to AmerisourceBergen Drug Corp for the supply of LINZESS 145 MCG capsules (30-count units), with an ultimate completion date of August 25, 2025. This competitively awarded, firm fixed-price delivery order was issued without a set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, has been selected to fulfill this medical supply requirement as part of its ongoing federal contracting relationship with DLA. This delivery order operates under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (contract number SPE2DX), a $999.99 billion global pharmaceutical support vehicle running through December 2026. The IDC enables the contractor to supply a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, including specialty medications, brand-name and generic drugs, vaccines, and related medical commodities. The current award reflects the company's established capacity to meet federal pharmaceutical procurement requirements and its role as a critical vendor supporting the Defense Health Agency and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.6k | 8/22/25 |